- Home
- SST vs IFRX Comparison
SST vs IFRX Comparison
Compare SST & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SST | IFRX |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | Germany |
| Employees | 300 | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4M | 60.6M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | SST | IFRX |
|---|---|---|
| Price | $1.89 | $0.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $10.00 | $8.50 |
| AVG Volume (30 Days) | 16.1K | ★ 187.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,054.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $0.71 |
| 52 Week High | $11.30 | $1.94 |
Technical Indicators
Market Signals| Indicator | SST | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 19.26 | 49.69 |
| Support Level | $0.34 | $0.75 |
| Resistance Level | $4.61 | $1.16 |
| Average True Range (ATR) | 0.32 | 0.07 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 12.96 | 38.89 |
Price Performance
Historical ComparisonAbout SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.